Featured Research

from universities, journals, and other organizations

New Treatment For Enlarged Heart Effective, New York Weill Cornell Study Shows

Date:
August 15, 2003
Source:
Cornell University
Summary:
Physician-scientists at Weill Cornell Medical College and NewYork-Presbyterian Hospital have demonstrated that, among hypertensive patients with electrocardiographic evidence of a type of enlarged heart condition called left ventricular hypertrophy (LVH), the drug Losartan is more likely to reduce the severity of their condition than the drug Atenolol.

New York, NY (August 12, 2003) -- Physician-scientists at Weill Cornell Medical College and NewYork-Presbyterian Hospital have demonstrated that, among hypertensive patients with electrocardiographic evidence of a type of enlarged heart condition called left ventricular hypertrophy (LVH), the drug Losartan is more likely to reduce the severity of their condition than the drug Atenolol. Losartan's benefits were demonstrated throughout the five-year study period, irrespective of a number of factors, including the severity of the condition. LVH, a condition in which the heart's lower-left chamber (left ventricle) has grown thicker, is a risk factor associated with heart failure, myocardial infarction, and cardiovascular death.

The study, published in the August 12 issue of Circulation, and available online, confirms earlier findings of the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension multicenter study of 9,193 hypertensive patients. The research shows that Losartan-based therapy was more effective at reducing LVH than the beta-blocker Atenolol, according to two electrocardiographic-based measurement standards: Sokolow-Lyon voltage and Cornell voltage-duration (Lancet 2002).

The current double-blind and randomized study, which uses patient data from the LIFE study, additionally finds that (1) Losartan compares favorably at six months, and at one-year intervals through five years; (2) the drug is effective irrespective of the severity of LVH and hypertension, or changes in blood pressure due to treatment; and (3) the drug is effective irrespective of patient gender, age, ethnicity, and presence of diabetes.

"By the first six months of treatment, patients treated with Losartan had a nearly three times greater reduction in LVH than those treated with Atenolol. We now know that these benefits continue through five years, and irrespective of a variety of factors," said Dr. Peter M. Okin, the study's principal investigator; Professor of Medicine at Weill Cornell Medical College; and Attending Physician at NewYork-Presbyterian Hospital.

Additionally, the current study suggests that Losartan has a direct effect on reducing the degree of LVH, independent of the drug's effect on reducing blood pressure. "This is suggested by the finding that Losartan treatment resulted in greater regression of LVH than Atenolol -- even though the two drugs produced almost identical reductions in both systolic and diastolic blood pressure," said Dr. Okin. "Further supporting this contention are the statistical analyses in which we adjusted for any possible differences between the treatment groups and still found a much greater reduction in LVH with Losartan. However, further study is required to assess this issue."

Left ventricular hypertrophy (LVH) is a response to an underlying cardiovascular condition, most commonly, high blood pressure. Other underlying conditions include valvular heart disease and coronary heart disease. The prevalence of LVH in patients with moderate-to-severe hypertension is approximately 20 to 25 percent.

The current study was co-authored by Dr. Richard B. Devereux, Professor of Medicine at Weill Cornell Medical College and Attending Physician at NewYork-Presbyterian Hospital. Dr. Devereux was also co-author of the original LIFE study published in Lancet.

Cornell product criteria were developed by Dr. Okin and others at NewYork Weill Cornell Medical Center, and have been demonstrated to be the most sensitive of standard ECG criteria for the detection of anatomic hypertrophy. Cornell product criteria were the predominant ECG criteria used to recruit patients in the LIFE study.

Losartan, an angiotensin receptor blocker (ARB), has been approved by the FDA for the treatment of hypertension and for reducing the risk of stroke in patients with hypertension. There has not yet been an application to the FDA to seek approval to treat and regress hypertrophy. Losartan is manufactured by Merck & Co. of New Jersey.

The study was funded by a grant from Merck & Co.


Story Source:

The above story is based on materials provided by Cornell University. Note: Materials may be edited for content and length.


Cite This Page:

Cornell University. "New Treatment For Enlarged Heart Effective, New York Weill Cornell Study Shows." ScienceDaily. ScienceDaily, 15 August 2003. <www.sciencedaily.com/releases/2003/08/030815074109.htm>.
Cornell University. (2003, August 15). New Treatment For Enlarged Heart Effective, New York Weill Cornell Study Shows. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2003/08/030815074109.htm
Cornell University. "New Treatment For Enlarged Heart Effective, New York Weill Cornell Study Shows." ScienceDaily. www.sciencedaily.com/releases/2003/08/030815074109.htm (accessed April 16, 2014).

Share This



More Space & Time News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

NASA Showcases Lunar Eclipse

NASA Showcases Lunar Eclipse

AP (Apr. 15, 2014) Star gazers in parts of North and South America got a rare treat early Tuesday morning - a total eclipse of the moon. (April 15) Video provided by AP
Powered by NewsLook.com
Spacecrafts Could Use Urine As Fuel Source

Spacecrafts Could Use Urine As Fuel Source

Newsy (Apr. 15, 2014) New research says the urea from urine could be recycled for fuel. Urea is filtered out of wastewater when making drinking water. Video provided by Newsy
Powered by NewsLook.com
NASA Approves Mon. Space Station Supply Launch

NASA Approves Mon. Space Station Supply Launch

AP (Apr. 13, 2014) NASA decided Sunday to stick with the planned launch of the SpaceX cargo ship, despite a critical computer outage at the space station.Liftoff is scheduled for 4:58 p.m. Monday from Cape Canaveral. (April 13) Video provided by AP
Powered by NewsLook.com
'Blood Moon' Attracts Stargazers, Conspiracy Theories

'Blood Moon' Attracts Stargazers, Conspiracy Theories

Newsy (Apr. 13, 2014) Tuesday's total lunar eclipse will bring out both stargazers and conspiracy theorists alike as the blood red moon fills up the early morning sky. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins